Bracebridge Capital LLC’s Aquestive Therapeutics AQST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.91M Hold
459,216
0.05% 30
2025
Q4
$2.97M Hold
459,216
0.1% 19
2025
Q3
$2.57M Hold
459,216
0.13% 20
2025
Q2
$1.52M Hold
459,216
0.08% 30
2025
Q1
$1.33M Hold
459,216
0.09% 21
2024
Q4
$1.63M Buy
459,216
+30,645
+7% +$141K 0.12% 24
2024
Q3
$2.13M Hold
428,571
0.35% 15
2024
Q2
$1.11M Hold
428,571
0.2% 12
2024
Q1
$1.83M Hold
428,571
0.23% 14
2023
Q4
$866K Hold
428,571
0.19% 13
2023
Q3
$656K Hold
428,571
0.1% 14
2023
Q2
$707K Hold
428,571
0.39% 20
2023
Q1
$489K Hold
428,571
0.13% 39
2022
Q4
$387K Hold
428,571
0.04% 65
2022
Q3
$501K Hold
428,571
0.09% 82
2022
Q2
$274K Hold
428,571
0.04% 86
2022
Q1
$1.12M Hold
428,571
0.08% 68
2021
Q4
$1.67M Hold
428,571
0.1% 60
2021
Q3
$1.87M Hold
428,571
0.17% 50
2021
Q2
$1.7M Hold
428,571
0.15% 47
2021
Q1
$2.23M Hold
428,571
0.19% 33
2020
Q4
$2.29M Hold
428,571
0.35% 13
2020
Q3
$2.08M Hold
428,571
0.33% 11
2020
Q2
$2.08M Hold
428,571
0.61% 10
2020
Q1
$1M Hold
428,571
0.18% 11
2019
Q4
$2M Buy
+428,571
New +$2.23M 0.16% 13

Other funds holding AQST

Bracebridge Capital LLC's AQST Position: Q1 2026 in Review

Bracebridge Capital LLC held its Aquestive Therapeutics (AQST) position steady in Q1 2026 at 459,216 shares worth $1.91M. The position accounts for 0.05% of the portfolio, ranked #30.

Bracebridge Capital LLC first reported a position in AQST in Q4 2019 and has held it in 26 quarters since. The position peaked at $2.97M in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Bracebridge Capital LLC held 459,216 shares of Aquestive Therapeutics worth $1.91M as of Q1 2026.
  • Bracebridge Capital LLC left its Aquestive Therapeutics share count unchanged in Q1 2026.
  • Aquestive Therapeutics made up 0.05% of Bracebridge Capital LLC's portfolio in Q1 2026, its #30 holding.
  • Bracebridge Capital LLC first reported a position in Aquestive Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • Bracebridge Capital LLC's Aquestive Therapeutics position peaked at $2.97M in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Bracebridge Capital LLC's 13F filing for Q1 2026, filed 15 May 2026.